A next-generation sequencing panel for cytology and needle core biopsy samples was able to meet the clinical molecular oncology need, compared to that of surgical resection samples.
A next-generation sequencing panel for cytology and needle core biopsy samples was able to meet the clinical molecular oncology need, compared to that of surgical resection samples.
Overexpression of HER2 in both cytology and surgical pathology specimens can be used to identify those patients with NSCLC who would benefit from HER2-targeted therapies.
Overexpression of HER2 in both cytology and surgical pathology specimens can be used to identify those patients with NSCLC who would benefit from HER2-targeted therapies.
